Neuropsychiatric conditions and\/or associated treatment linked to increased risk for severe outcomes from COVID-19, SARIs<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, Nov. 16, 2022 (HealthDay News) — People with neuropsychiatric conditions and\/or associated treatment have an increased risk for severe outcomes from COVID-19 and from other severe acute respiratory infections (SARIs), according to a study published online Nov. 9 in JAMA Psychiatry<\/em>.<\/p>\n Tom Alan Ranger, Ph.D., from the University of Oxford in the United Kingdom, and colleagues examined whether neuropsychiatric conditions are associated with severe outcomes from COVID-19 infection and other SARIs in prepandemic (2015 to 2020) and contemporary (2020 to 2021) longitudinal cohorts (11,134,789 adults [223,569 SARI cases] and 8,388,956 adults [58,203 severe COVID-19 cases], respectively).<\/p>\n The researchers observed an association for diagnosis and\/or treatment for neuropsychiatric conditions other than dementia with an increased likelihood of a severe outcome from SARI (hazard ratios, 1.16 and 2.56 for anxiety diagnosis and psychotic disorder diagnosis and treatment, respectively) and COVID-19 (hazard ratios, 1.16 and 2.37 for anxiety diagnosis and psychotic disorder treatment, respectively). Compared with SARI, those with COVID-19 had a higher effect estimate for severe outcome with dementia (hazard ratio, 2.85 versus 2.13).<\/p>\n “The adjusted results comparing severe outcomes from COVID-19 disease and other SARI largely seemed similar, suggesting that the associations were not disease specific,” the authors write. “Although dementia was associated with a higher increased risk of severe outcome from COVID-19 than for SARI, well-documented impacts of the pandemic on specific care settings mean that this result should be interpreted with caution.”<\/p>\n Several authors disclosed financial ties to industry.<\/p>\n